View clinical trials related to Locally Advanced Lung Carcinoma.
Filter by:The goal of this single arm, phase II clinical trial is to evaluate the efficacy and safety of cadonilimab (AK104) as induction and consolidation therapy in locally advanced/unresectable non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy. Participants will receive 2 cycles of induction therapy with cadonilimab combined with EP regimen, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy +EP regimen chemotherapy), and finally consolidation therapy with cadonilimab (AK104) for 1 year.